| Project/Area Number |
20591259
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
SHIMA Midori Nara Medical University, 医学部, 教授 (30162663)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHIBATA Masaru 奈良県立医科大学, 医学部, 講師 (50405388)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2010: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2009: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2008: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
|
|---|
| Keywords | 小児血液学 / 第VIII因子 / 第VIII因子活性 / 血友病A / 活性化 / モノクローナル抗体 / トロンビン / 活性型第X因子 / A2ドメイン / 抗体療法 |
|---|
| Research Abstract |
Antibodies that promote FVIII activity do not appear to have been reported. In this study, anti-FVIII monoclonal antibody, mab216, that enhanced FVIII coagulation activity. The mab216 increased FVIII activity ～1.5-fold dose-dependently, FXa generation and thrombin generation were increased by ～1.4- and ～2.5-fold, respectively. An anti A2 epitope was identified and the antibody enhanced the cleavage at Arg372. The findings may cast new light on new principles for improving the treatment of haemophilia A patients.
|
